BIOINFORMATICS MARKET ANALYSIS

Market News

Global Bioinformatics Market: Key Developments

On April 13, 2023, Agilent Technologies Inc., which delivers complete scientific solutions, helping customers achieve superior outcomes in their labs, clinics, and business, announced the launch of the Agilent SureSelect Cancer CGP Assay designed for somatic variant profiling for a broad range of solid tumor types. The pan-cancer assay design is based on an NGS panel comprising 679 genes globally curated from leading cancer databases and in partnership with key clinical cancer researchers. The assay workflow is efficient, automatable, and flexible, making tumor molecular profiling more accessible to the broad clinical research community.

In July 2021, the National Institute of Technology, Rourkela (NIT-R), India, launched its Center for Bioinformatics and Computational Biology (CBCB), which helps develop novel disease biomarkers and therapeutic strategies using big data analysis. Thus, the launch of such centers using computational biology in developing countries is boosting market growth.

In January 2021, Life Technologies is a global biotechnology tools company providing premier systems, consumables, and services for scientific researchers announced the acquisition of Compendia Bioscience, a preeminent cancer bioinformatics company widely used by the pharmaceutical industry to identify novel gene targets for drug discovery and development. Its deep oncology expertise and high-value, proprietary assets enhance Life's diagnostic development capabilities across multiple platforms, including next-generation sequencing, qPCR, and proteome analysis.

In January 2021, Affymetrix, Inc., which enables the flexible throughput analysis of genotyping, chromosome copy number variations and gene expression, announced an expanded licensing program that makes some of its most recently issued patents, as well as early patents in microarrays. The patents include intellectual property in areas such as DNA and protein arrays, scanner/detector technology, and microfluidics, as well as a broadened portfolio of patents related to the use of beads to measure nucleic acids or peptide binding for genomic analysis.

In April 2021, Bio-Rad Laboratories develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets, has purchased the next-generation sequencing technology firm GnuBIO platform is an innovative desktop sequencer which incorporates all the functions of DNA sequencing into a single, integrated system.